Elizabeth Shaheen, Vice President, Oncology Business Unit, Strategy at AstraZeneca, shared on LinkedIn:
“Just returned from a visit to China. Impossible to believe it was ten years ago now I lived there.
As was then, as is now, innovation is thriving.
It is clear the next generation of novel oncology medicines will come from a truly global innovation ecosystem – and China one of the leaders.
A big thank you to Astra Zeneca China colleagues for their commitment to work together and bring transformative new medicines to patients in China and around the world.”
Read other articles on OncoDaily.
